COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes

0558632 - BC 2023 RIV CH eng J - Journal Article
Bigdelou, B. - Sepand, M. - Najafikhoshnoo, S. - Negrete, J. - Sharaf, M. - Ho, J. - Sullivan, I. - Chauhan, Prashant - Etter, M. - Shekarian, T. - Liang, O. - Hutter, G. - Esfandiarpour, R. - Zanganeh, S.
COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes.
Frontiers in Immunology. Roč. 13, MAY (2022), č. článku 890517. ISSN 1664-3224. E-ISSN 1664-3224
Institutional support: RVO:60077344
Keywords : insulin-resistance * sex-differences * adipose-tissue * cytokine storm * liver-disease * alcohol-use * coronavirus * infections * obesity * mechanisms * coronavirus disease 2019 * covid-19 * immune responses * cancer * cardiovascular disease * diabetes * treatment implications
OECD category: Immunology
Impact factor: 7.3, year: 2022
Method of publishing: Open access
https://www.frontiersin.org/articles/10.3389/fimmu.2022.890517/full

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated symptoms, named coronavirus disease 2019 (COVID-19), have rapidly spread worldwide, resulting in the declaration of a pandemic. When several countries began enacting quarantine and lockdown policies, the pandemic as it is now known truly began. While most patients have minimal symptoms, approximately 20% of verified subjects are suffering from serious medical consequences. Co-existing diseases, such as cardiovascular disease, cancer, diabetes, and others, have been shown to make patients more vulnerable to severe outcomes from COVID-19 by modulating host-viral interactions and immune responses, causing severe infection and mortality. In this review, we outline the putative signaling pathways at the interface of COVID-19 and several diseases, emphasizing the clinical and molecular implications of concurring diseases in COVID-19 clinical outcomes. As evidence is limited on co-existing diseases and COVID-19, most findings are preliminary, and further research is required for optimal management of patients with comorbidities.
Permanent Link: https://hdl.handle.net/11104/0338443